ttorney Docket No. 2300-19545 (PP19545.003)

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 10/20/03.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re	application of	HOUGHTON
111 10	application of	HOULINOULL

Serial No.:

10/612,884

Examiner:

Unassigned

Confirmation No.:

Art Unit:

Unassigned

Filed:

July 2, 2003

For:

HCV FUSION PROTEINS WITH MODIFIED NS3 DOMAINS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §\$1.97 and 1.98.

y	submit	s the following information in conformance with 37 C.F.R. §§1.97 and 1.98.
	[X]	Pursuant to 37 C.F.R. §1.98, a copy of each document cited in the attached Form PTO/SB/08 is enclosed.
	[]	No copies of the publications listed on the attached Form PTO/SB/08A are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No to which the above-identified application claims priority under 35 U.S.C. §120.
		Publication(s) listed on the attached Form PTO/SB/08A were cited in a foreign search or examination report corresponding to application serial no and mailed on
	[]	Enclosed is a copy of a non-English publication(s) Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).
	[]	Enclosed is a copy of a non-English publication(s) English language publication (copy enclosed) claims priority from this non-English publication.

	[]	Enclosed is an explanation of non-English publication(s) for which an English translation is not available.
		Enclosed is an English translation of non-English publication(s)cited in the attached Form PTO/SB/08A.
	[]	Enclosed is a copy of pending patent Application Serial No
	This Ir	nformation Disclosure Statement is filed within any one of the following time
periods	s:	
		within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);
	[]	within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in this international application;
	[X]	before the mailing date of a first office action on the merits; or
	[]	before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. §1.114.
	It is ro	specifully requested that the Eveniner consider the shove noted information and

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.

Please direct all further written communications in this application to:

Alisa A. Harbin Chiron Corporation Intellectual Property – R440 P.O. Box 8097 Emeryville, CA 94662-8097

Dated: 10 20 03

Respectfully submitted,

Chiron Corporation Intellectual Property – R440 P.O. Box 8097 Emeryville, CA 94662-8097

Tel: (650) 493-3400 Fax: (650) 493-3440 By:

Roberta L. Robins Reg. No. 33,208



Attorney Docket No. 2300-19545 (PP19545.003)

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 10/20/03.

Yang Tang

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of HOUGHTON

Serial No.: 10/612,884

Examiner: Unassigned

Confirmation No.:

Art Unit:

Unassigned

Filed:

July 2, 2003

For:

HCV FUSION PROTEINS WITH MODIFIED NS3 DOMAINS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Enclosed is an Information Disclosure Statement and accompanying Form PTO/SB/08A for the above-identified patent application.

[X]	In accordance with 37 C.F.R.	§1.97(b), no	additional	fee for sul	bmission o	f
	the IDS is required.					

- [] In accordance with 37 C.F.R. §1.97(c), also enclosed is:
 - [] the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p); or
 - [] a statement as specified in 37 C.F.R. §1.97(e).
- [] In accordance with 37 C.F.R. §1.97(d), a statement as specified in 37 C.F.R. § 1.97(e) and the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) are also enclosed.
- [] Check No. ___ in the amount of \$___ for the total fee is attached.

Page 2

- [X] A return receipt postcard is also enclosed.
- [] Please charge \$____ to Deposit Account No. 18-1648 for the total fee. This paper is being submitted in duplicate.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 18-1648.

Please direct all further written communications in this application to:

Alisa A. Harbin Chiron Corporation Intellectual Property – R440 P.O. Box 8097 Emeryville, CA 94662-8097

Dated: 16 20 03

Respectfully submitted,

Chiron Corporation Intellectual Property – R440 P.O. Box 8097 Emeryville, CA 94662-8097

Tel: (650) 493-3400 Fax: (650) 493-3440 By:

Roberta L. Robins Reg. No. 33,208 Please type a plus sign (+) inside this box > +

Si Si	ubstitute for form 14	149A/PT0	0		Complete if Known		
′		Application Number	10/612,884				
I	NFORMATIO	ON DI	SCLOSURE	Filing Date	July 2, 2003		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	HOUGHTON		
	,			Group Art Unit	Unassigned		
	(use as many s	heets as	s necessary)	Examiner Name	Unassigned		
Sheet	1	of	3	Attorney Docket Number	2300-19545 (PP19545.003)		

U.S. PATENT DOCUMENTS						
		U.S. Patent Document			Date of Publication of Cited	
Examiner Initials*	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Document MM-DD-YYYY	
	A1	5,372,928	A	Miyamura et al.	12-13-1994	
			<u> </u>			
	ļ					
						
	1		1			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite Foreign Patent Document		ument	N	Date of Publication		
iiitiais ·	140.	Office ²	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	T ⁶
	B1	EP	0 693 687	Al	Chiron Corporation	01-24-1996	
	B2	WO	01/38360	A2	Chiron Corporation	05-31-2001	
					· · · · · · · · · · · · · · · · · · ·		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

ease type a plus sign (+) inside this box 👈

Complete if Known Substitute for form 1449B/PTO **Application Number** 10/612,884 Filing Date July 2, 2003 INFORMATION DISCLOSURE HOUGHTON First Named Inventor STATEMENT BY APPLICANT Group Art Unit Unassigned Examiner Name Unassigned (use as many sheets as necessary) Sheet 2 of 3 Attorney Docket Number 2300-19545 (PP19545.003)

Examiner	Cite	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	T ²
Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1*
	Cl	BARTENSCHLAGER et al., "Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions," J. Virology 67:3835-3844, 1993	
	C2	BOTARELLI et al., "T-lymphocyte response to hepatitis C virus in different clinical courses of infection," Gastroenterology 104:580-587, 1993	
-:	C3	CHEN et al., "Human and murine antibody recognition is focused on the ATPase/Helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein," <i>Hepatology</i> 28:219-224, 1998	
	C4	COOPER et al., "Analysis of a successful immune response against hepatitis C virus," <i>Immunity</i> 10:439-449, 1999	
	C5	DIEPOLDER et al., "Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection," <i>Lancet</i> 346:1006-1007, 1995	
	C6	DIEPOLDER et al., "Immunodominant CD4 T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection," J. Virology 71:6011-6019, 1997	
	C7	FERRARI et al., "T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections," <i>Hepatology</i> 19:286-295, 1994	
	C8	HOFFMAN et al., "Mapping of immunodominant CD4 T lymphocyte epitiopes of hepatitis C virus antigens and their relevance during the course of chronic infection," <i>Hepatology</i> 21:632-638, 1995	
	C9	IWATA et al., "Interferon gamma production by peripheral blood lymphocytes to hepatitis C virus core protein in chronic hepatitis C infection," <i>Hepatology</i> 22:1057-1064, 1995	
	C10	MINUTELLO et al., "Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4 T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C," J. Exp. Med. 178:17-25, 1993	
	C11	MISSALE et al., "Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response," J. Clin. Invest. 98:706-714, 1996	

ı	Examiner	Date	
ı	Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number.
 Applicant is to place a check mark here if English language Translation attached.

Please type a plus sign (+) inside this box > +

Substitute for form 1449B/PTO

Application
Filing Dat
First Nam
Group Art

Complete if Known

Application Number 10/612,884

Filing Date July 2, 2003

First Named Inventor HOUGHTON

Group Art Unit Unassigned

Examiner Name Unassigned

2300-19545 (PP19545.003)

(use as many sheets as necessary)
Sheet 3 of 3

Examiner
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

C12
TSAI et al., "Detection of type 2-like T-helper rells in hepatitis C virus infection: implications for hepatitis C virus chronicity," "Hepatology 25:449-458, 1997

C13
TSAI et al., "Cellular immune responses in patients with dual infection of hepatitis B and C viruses: dominant role of hepatitis C virus," Hepatology 21:908-912, 1995

Attorney Docket Number

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner	· · · · · · · · · · · · · · · · · · ·	Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² Applicant is to place a check mark here if English language Translation attached.